(Sharecast News) - Drugmaker GSK said on Monday that its relapsed/refractory multiple myeloma treatment Blenrep had received approval from China's National Medical Products Administration, making it the only anti-BCMA cleared for use in the country.
GSK said Blenrep's Chinese approval followed a priority review of its application and Breakthrough Therapy Designation...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE